Mortality, stroke rates similar at 5-years with TAVR versus SAVI: SURTAVI trial
Delhi: Patients at intermediate surgical risk who underwent transcatheter aortic valve replacement (TAVR) versus surgery had similar rates of mortality or stroke, according to five-year data from the SURTAVI trial. However, there were more reinterventions after TAVR initially, the rates were similar after two years and also key clinical endpoints were similar. The findings from the...
Delhi: Patients at intermediate surgical risk who underwent transcatheter aortic valve replacement (TAVR) versus surgery had similar rates of mortality or stroke, according to five-year data from the SURTAVI trial. However, there were more reinterventions after TAVR initially, the rates were similar after two years and also key clinical endpoints were similar.
The findings from the Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI) Trial were presented at TCT 2021, the 33rd annual scientific symposium of the Cardiovascular Research Foundation (CRF).
Surgical Aortic Valve Replacement (SAVR) has been viewed as the norm of care in the past few decades, but recent years have seen a generous ascent in the minimally invasive transcatheter aortic valve replacement (TAVR) technology, even in low-risk surgical patients.
According to Nicolas M. Van Mieghem, professor of interventional cardiology, Thoraxcenter, Erasmus University Medical Center, Rotterdam, the Netherlands, longer-term outcomes data from the SURTAVI randomized trial comparing early-generation TAVR to open-heart surgery are similar and encouraging for TAVR in younger, healthier patients with aortic stenosis.
The study enrolled intermediate-risk patients across 87 centers in Canada, Europe, and the United States who underwent attempted implant of a transcatheter aortic valve (n=864) or a surgical valve (n=796). Categorization was made among these patients based on investigational sites and the need for revascularization. Concomitant or staged PCI in the TAVR arm or coronary bypass graft in the surgical arm was performed as indicated.
Following were the study's key findings:
- The primary endpoint, consisting of the composite of death or disabling stroke at five years, was similar in both groups with 31.3% for TAVR and 30.8% for surgery.
- All-cause mortality had similar rates and disabling stroke was 4.1% for TAVR compared to 5.8% for surgery.
- At two years, reinterventions were higher with TAVR (2.5% versus 0.5%). However, at years three through five, the rates were similar.
- At five years, the reintervention rate for TAVR was 1.0% compared to 1.3% compared with surgery.
- Core lab-assessed valve regurgitation showed that surgery patients had significantly less ≥ mild aortic regurgitation or paravalvular leak than TAVR at one, two, and five-year follow-ups.
- Kansas City Cardiomyopathy Questionnaire summary scores were higher for TAVR patients at one year. However, the scores were similar at each additional follow-up through five years. New York Heart Association Class was also similar between both groups at each follow-up. In addition, forward-flow hemodynamics were significantly better with TAVR.
To sum up, there were no differences in the 5-year outcomes in intermediate-risk patients with SAVR versus TAVR.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd